



Name/DOB: **Test, Test (1/1/1985)**
Patient ID: test
Collected Date: 9/14/2022 1:03 PM
Approval date: 9/14/2022 1:07 PM

Sex: F
Age: 37

Provider: Campbell, Lucas, MD
Sample ID: 220914001
Entered by: Ashton Leehans

Auria

Approved By: Leehans, Ashton

Auria Score -3.9161



Auria Score Interpretation
09/14/22 1:03 PM

Low

Auria™ is a short-term breast health assessment adjunct clinical test intended to be used based on the independent medical judgement of the ordering physician in conjunction with the patient’s medical history and result of standard of care testing. Auria™ is not a replacement for a screening mammogram. It is recommended that an Auria™ classification of High be clinically correlated with a structural examination of the breast tissue within 3 to 6 months of receiving test results. It is recommended that an Auria™ classification of Medium be clinically correlated with a structural examination of the breast tissue, such as a mammography, within 6 to 12 months of receiving test results. It is recommended that an Auria™ classification of Low be clinically correlated with a structural examination of the breast tissue, such as a mammography, within 12 to 18 months of receiving test results.

Auria™ test type: Composite algorithmic analysis of tear protein biomarkers. Quantitative values of individual biomarkers are not reportable and are not associated with individual biomarker result reference ranges.

Precautions and limitations: Auria™ is intended as a short-term breast health assessment for women ages 33-85 at average risk of developing breast cancer. Assigned classifications are associated with the indication that protein levels detected by the Auria™ test may be associated with the development of an abnormality in the breast tissue. Auria™ is not a diagnostic test for breast cancer.

Auria™ may produce a false positive or false negative result. An Auria Score™ below 0.1 does not guarantee the absence of an abnormality in the breast tissue or breast cancer. Patients with an Auria Score™ below 0.1 should be advised to continue participating in breast health standard care testing for their age group. An Auria Score™ above 0.1 does not guarantee the presence of an abnormality in the breast tissue or breast cancer. Patients with an Auria Score™ above 0.1 should be referred for breast imaging.

Auria™ is a lab developed test and its performance characteristics were determined by Namida Lab, Inc. It has not been cleared or approved by the U. S. Food and Drug Administration (FDA). The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. Namida Lab, Inc. is regulated under the Clinical Improvements



Name/DOB: **Test, Test (1/1/1985)**
Patient ID: test
Collected Date: 9/14/2022 1:03 PM
Approval date: 9/14/2022 1:07 PM

Sex: F
Age: 37

Provider: Campbell, Lucas, MD
Sample ID: 220914001
Entered by: Ashton Leehans

Auria (cont'd) Approved By: Leehans, Ashton

Amendment (CLIA) as qualified to perform high-complexity clinical testing.